Aeon Biopharma provides update on development pipeline

Aeon Biopharma provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our early-stage clinical programs, we have multiple late-stage programs designed to show the safety and efficacy of ABP-450 in the treatment of various indications. Several of these programs are ready to advance into the next stage of clinical development. When taking into consideration our clinical pipeline and combining it with our differentiated business model, we see a number of compelling opportunities to pursue,” said CEO Marc Forth. “While we were disappointed that ABP-450 did not demonstrate statistically significant superiority over placebo in its interim Phase 2 readout for chronic migraine, this does not diminish our enthusiasm for our migraine program, which includes our issued patent for our novel migraine injection paradigm, nor the other indications that have well-founded scientific rationale to pursue in clinical trials.” Completed Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. Ready to initiate a Phase 3 study of ABP-450 in cervical dystonia, pending finalization of the trial protocol. Ready for a Phase 2 study of ABP-450 in gastroparesis; IND already cleared by the FDA. IND-enabling studies are already planned, which are designed to support the development of ABP-450 in PTSD.